What Is Phleomycin? Definition and What Research Reports

Definition

Phleomycin is a copper-binding glycopeptide antibiotic isolated from cultures of the actinomycete Streptomyces verticillus, and it belongs to the same natural-product family as bleomycin. In laboratory usage the name is applied both to the mixture of related congeners and to purified phleomycin D1, the form distributed commercially under the trade name Zeocin. Its defining chemical feature is that it associates with DNA and, in the presence of metal ions and oxygen, promotes strand cleavage, which is why it is cytotoxic across bacteria, fungi, algae, plants and animal cells. Because resistance can be conferred by a single small bleomycin-binding protein encoded by the ble (also written bleR or Sh ble) gene, phleomycin is used mainly as a dominant selectable marker in genetic transformation and as a controlled source of DNA damage in genome-stability research. This page is for educational purposes only and is not medical advice; consult a licensed physician for any questions about medical treatment.

What Class of Molecule Is Phleomycin?

Phleomycin is classed as a glycopeptide (more precisely, a glycopeptide-derived non-ribosomal natural product), meaning its structure combines a peptide-like backbone assembled by bacterial enzymes with attached sugar residues and a metal-binding domain. It is not a signalling peptide, a peptide hormone or a peptide analogue of the kind usually discussed in therapeutic peptide literature; it is a small microbial secondary metabolite whose peptide character is structural rather than receptor-directed. Its biological activity depends on metal coordination and oxygen chemistry at the DNA interface rather than on binding a cell-surface receptor.

Phleomycin, bleomycin and Zeocin

The three names are frequently confused in method sections. Bleomycin is the closely related congener family developed as an anticancer agent; phleomycin differs in the bithiazole portion of the molecule and has generally been retained as a laboratory reagent; Zeocin is a commercial preparation of phleomycin D1 marketed for cell-culture selection. The shared resistance mechanism explains why the same ble cassette is described in the literature as conferring "phleomycin", "bleomycin" or "zeocin" resistance depending on the reagent a laboratory happens to use.

How the Term Is Used in Peptide and Molecular Biology Research

In practice, researchers encounter "phleomycin" in two distinct experimental roles.

• Selection agent. Cells that have taken up a plasmid or cassette carrying the bleomycin-binding resistance gene survive on phleomycin-containing medium, while untransformed cells do not, allowing transformants to be recovered without nutritional auxotrophy markers. A 2025 report described CRISPR/Cas9-compatible plasmids enabling seven dominant genetic selection methods for the human fungal pathogen Cryptococcus neoformans, a toolkit in which drug-resistance markers of this type are central (PMID 40996288).
• Genotoxin. Because the molecule generates DNA strand breaks, it is applied at sub-lethal concentrations to test whether a gene of interest is needed for double-strand break repair or genome maintenance. Sensitivity to phleomycin in a mutant background is interpreted as evidence of a repair defect, an approach reflected in work on DksA and DNA double-strand break repair (PMID 31076845).

Peptide-focused readers most often meet the term indirectly: recombinant peptide and protein expression in yeast, filamentous fungi, microalgae or mammalian cell lines routinely relies on phleomycin/zeocin selection to establish stable expression lines. In that context the compound is part of the construction workflow, not part of the product.

What the Published Literature Reports

Transformation and selection

A 2009 study in Applied and Environmental Microbiology reported that phleomycin increased transformation efficiency and promoted single integrations in the basidiomycete Schizophyllum commune, a finding relevant to laboratories seeking clean, single-copy insertions (PMID 19114524). Comparable selection strategies appear across widely different organisms: a 2015 report described transformation of the green seaweed Ulva mutabilis using vector plasmids that integrated into the genome (PMID 26986891), and a 2020 paper validated a new multicistronic plasmid for efficient and stable expression of transgenes in microalgae (PMID 31979077). Metabolic-engineering programmes use the same logic: the study describing metabolic engineering of Ustilago trichophora TZ1 reported improved malic acid production from engineered strains (PMID 29142828), and a 2019 report found that overexpression of a DOF-type transcription factor enhanced lipid synthesis in Chlorella vulgaris (PMID 30877635).

DNA damage and repair phenotyping

The second body of literature treats phleomycin as an experimental stressor. In fission yeast, researchers reported that Rgf1p, a Rho1p GEF, is required for double-strand break repair (PMID 28334931). In budding yeast, a 2021 study in the Journal of Biological Chemistry described catalysis-dependent and redundant roles for Dma1 and Dma2 in the maintenance of genome stability in Saccharomyces cerevisiae (PMID 33933452). Work in human cells has used related damage-sensitivity logic: one report concluded that the chromatin-remodelling enzyme ALC1/CHD1L is required for efficient base excision repair (PMID 29149203), and a 2023 clinical-genetics study reported that loss of function of FIGNL1, a DNA damage response gene, causes human ovarian dysgenesis (PMID 37740949). Taken together, these papers illustrate the two reasons the term recurs: it names a selection pressure, and it names a way of interrogating repair pathways.

Where Phleomycin Appears in the Literature

Phleomycin in Research Systems: What Studies Report

The published reports summarised here are microbiological, cell-biological and genetic; none of them is a human safety or clinical dosing study of phleomycin, and the verified literature reviewed for this entry does not contain human exposure data. What the studies do report is expected cellular toxicity: the compound kills or inhibits cells that lack a resistance cassette, which is precisely the property that makes selection possible, and it produces measurable repair phenotypes in mutants, as in the fission-yeast work reporting that Rgf1p is required for double-strand break repair (PMID 28334931). Because the reagent damages DNA, it is handled as a genotoxic laboratory chemical under institutional biosafety and chemical-hygiene rules. Nothing in this entry describes or endorses use in humans or animals.

Common Points of Confusion

1. It is not a therapeutic peptide. Despite being a glycopeptide, phleomycin is an antibiotic-class natural product used as a reagent, not a peptide therapeutic candidate.
2. The resistance gene is not the drug. The ble-type bleomycin-binding protein is the marker; phleomycin is the pressure applied against it.
3. Names are interchangeable in papers but not in chemistry. Phleomycin, bleomycin and zeocin share a resistance mechanism yet differ as molecules and in how they are used.
4. Selection outcomes are organism-specific. The 2009 Schizophyllum commune study reported effects on integration pattern in that system, and researchers did not generalise those results to all hosts (PMID 19114524).

References

• CRISPR/Cas9-compatible plasmids enabling seven dominant genetic selection methods for the human fungal pathogen Cryptococcus neoformans (Microbiology Spectrum, 2025)
• Phleomycin increases transformation efficiency and promotes single integrations in Schizophyllum commune (Applied and Environmental Microbiology, 2009)
• DksA and DNA double-strand break repair (Current Genetics, 2019)
• Catalysis-dependent and redundant roles of Dma1 and Dma2 in maintenance of genome stability in Saccharomyces cerevisiae (Journal of Biological Chemistry, 2021)
• Rgf1p (Rho1p GEF) is required for double-strand break repair in fission yeast (Nucleic Acids Research, 2017)
• ALC1/CHD1L, a chromatin-remodeling enzyme, is required for efficient base excision repair (PLoS One, 2017)
• Loss of function of FIGNL1, a DNA damage response gene, causes human ovarian dysgenesis (European Journal of Endocrinology, 2023)
• Transformation of Ulva mutabilis (Chlorophyta) by vector plasmids integrating into the genome (Journal of Phycology, 2015)
• Validation of a New Multicistronic Plasmid for the Efficient and Stable Expression of Transgenes in Microalgae (International Journal of Molecular Sciences, 2020)
• Metabolic engineering of Ustilago trichophora TZ1 for improved malic acid production (Metabolic Engineering Communications, 2017)
• Overexpression of the DOF-Type Transcription Factor Enhances Lipid Synthesis in Chlorella vulgaris (Applied Biochemistry and Biotechnology, 2019)